Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Omalizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 974,765Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 20Xolair

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 2,028

    2018 Revenue in Millions : 1,969

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2020 Revenue in Millions : 1,251

    2019 Revenue in Millions : 1,173

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2020 Revenue in Millions : 2,121

    2019 Revenue in Millions : 2,194

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2021 Revenue in Millions : 1,428

    2020 Revenue in Millions : 1,251

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2021 Revenue in Millions : 2,090

    2020 Revenue in Millions : 2,018

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 1,365

    2021 Revenue in Millions : 1,428

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 2,414

    2021 Revenue in Millions : 2,090

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 2,525

    2022 Revenue in Millions : 2,414

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 1,463

    2022 Revenue in Millions : 1,365

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Xolair

    Omalizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Xolair

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Novartis

    Omalizumab

    Main Therapeutic Indication : Respiratory Disorders

    Currency : USD

    2014 Revenue in Millions : 26.80%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF